by Madaline Spencer | Dec 9, 2024
Obi Umeh, MD, VP, Franchise Global Program Leader at Takeda, discusses positive interim results from study of mezagitamab for IgA nephropathy. IgA nephropathy is a kidney disorder that occurs when IgA accumulates in the kidneys. In the early stages,...
by Madaline Spencer | Dec 6, 2024
Darcy Trimpe, PhD, U.S. Medical Director at Amgen, discusses real world data on Tavneos (avacopan) for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). GPA is a type of vasculitis of the blood vessels. The disease can...
by Madaline Spencer | Dec 5, 2024
Carla Nester, MD, University of Iowa Stead Family Children’s Hospital, discusses results from the clinical trial of iptacopan in complement 3 glomerulopathy (C3G). C3G is a rare kidney disease characterized by damage to kidney glomeruli due to abnormal...
by Madaline Spencer | Dec 4, 2024
Jack Johnson, Co-Founder and Executive Director of the Fabry Disease Support and Information Group, and VP of the Fabry International Network, discusses the phase 3 BRIGHT study testing Elfabrio (pegunigalsidase alfa-iwx) in patients with Fabry disease. ...
by Madaline Spencer | Dec 3, 2024
Reena Sharma, MD, Salford Royal Hospital and University of Manchester, UK, discusses clinical data from a clinical trial testing an AAV gene therapy in patients with Gaucher disease. Clarification (around 8:52): *malignancies Gaucher disease refers to a group...
